Company Profile
Cue Biopharma Inc Stock Price, News & Catalysts
- Ticker:
- CUE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
37.84 USD (+10.74%)
Close
Last updated: September 17, 2026
116M USD
Market cap
Why the stock is moving
The latest monitored company update is “Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria.” The corresponding closing-price reaction is not yet available.
Company overview
Immune-Mediated Disease Portfolio
Cue Biopharma is a clinical-stage biotechnology company developing therapies for allergic and autoimmune diseases. Its portfolio combines a conventional antibody program with an Immuno-STAT platform designed to selectively regulate disease-driving immune cells.
CUE-221
CUE-221 is a dual-mechanism anti-IgE antibody being developed for allergic diseases. The program is in Phase 2 development for chronic spontaneous urticaria, while the company has also submitted an investigational new drug application to evaluate the candidate in food allergy.
Immuno-STAT Platform
The Immuno-STAT platform is designed to engage selected T-cell populations in vivo rather than broadly suppressing the immune system. Cue is applying the platform to autoimmune disease with the goal of reducing inflammation while promoting regulatory T-cell-mediated immune tolerance.
CUE-401
CUE-401 is the company's lead autoimmune Immuno-STAT candidate. It is designed to expand and activate regulatory T cells associated with control of inflammatory responses and is advancing toward first-in-human development.
Future catalysts
- Phase 2 CUE-221 data in chronic spontaneous urticaria by the end of Q3 2026.
- IND submission for CUE-401 by year-end 2026.
- Initiation of a Phase 1 study of CUE-401 by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc (CUE) most recently closed at 37.84 USD, a +10.74% move versus the previous session.
What is the market cap of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc currently has a market capitalization of 116M USD on BioPharmSignal.
What does Cue Biopharma Inc do?
Immune-Mediated Disease Portfolio Cue Biopharma is a clinical-stage biotechnology company developing therapies for allergic and autoimmune diseases. Its portfolio combines a conventional antibody program with an Immuno-STAT platform designed to selectively regulate disease-driving immune cells. CUE-221 CUE-221 is a dual-mechanism anti-IgE antibody being...
On which exchange is CUE stock listed?
Cue Biopharma Inc (CUE) is associated with NASDAQ, United States, Biopharma.
What is CUE-221?
Phase 2 CUE-221 data in chronic spontaneous urticaria by the end of Q3 2026.
Which conditions is Cue Biopharma Inc targeting with CUE-221?
Cue Biopharma Inc is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Cue Biopharma Inc describe recent progress with CUE-221?
Phase 2 CUE-221 data in chronic spontaneous urticaria by the end of Q3 2026.
What is CUE-401?
CUE-401 CUE-401 is the company's lead autoimmune Immuno-STAT candidate.